| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
RESEARCH |
1 Department of Obstetrics and Gynaecology, National University of Ireland, Galway, Clinical Science Institute, University College Hospital, Newcastle Road, Galway, Ireland and 2 National Centre for Biomedical Engineering Science, National University of Ireland, Galway, Ireland
Correspondence should be addressed to J J Morrison; Email: john.morrison{at}nuigalway.ie
| Abstract |
|---|
|
|
|---|
(8-iso PGF2
) and 8-iso prostaglandin E2 (8-iso PGE2), on umbilical artery tone, were mediated via the Rho kinase pathway. Real-time RT-PCR using primers for Rho A, ROCK I and ROCK II was performed on total RNA isolated from umbilical artery specimens obtained from normotensive and pre eclamptic women. The effects of both isoprostanes (n = 6) (in the absence and presence of the specific Rho kinase inhibitor Y-27632), on umbilical artery tone were measured, and compared with control recordings. Rho A mRNA expression levels were significantly lower in umbilical artery samples obtained from pre eclamptic women (n = 4) in comparison to those from normotensive women (n = 6) (P < 0.05). ROCK I and ROCK II mRNA levels were similar in both vessel types (P > 0.05). Both isoprostanes exerted a significant concentration-dependent vasocontractile effect (n = 7) (P < 0.001) on umbilical artery. For 8-iso PGE2, this effect was antagonised by Y-27632 (n = 6) (P < 0.01). The significant reduction of Rho A mRNA levels in umbilical arteries from pregnancies complicated by pre eclampsia may serve to counteract the diminished perfusion associated with the pathophysiology of pre eclampsia. The vasocontractile effect of 8-iso PGE2 in pre eclampsia may in part be mediated via the Rho kinase pathway. | Introduction |
|---|
|
|
|---|
Research has indicated that the process of calcium sensitisation (increase in smooth muscle tension and/or phosphorylation of myosin light chains at a constant [Ca2+]i by inhibition of myosin light chain phosphatase (MLCP)), is of major importance in regulating the state of vasoconstriction of vascular smooth muscle (Somlyo & Somlyo 2000). It is now apparent that the small G protein, Rho A is associated with inhibition of MLCP (Uehata et al. 1997, Kunihiko et al. 1999). Although the precise mechanism of action is unknown, two target proteins of Rho A, ROCK I and its isoform ROCK II, which are collectively known as Rho kinases, have a major role in Rho A-mediated calcium sensitisation. Upon activation, they enhance Rho-mediated calcium sensitisation and hence smooth muscle contractility. It is now clear that this Rho kinase pathway plays a central role in the pathogenesis of hypertension in animal models, in humans and in various situations of increased peripheral vascular resistance observed in hypertensive disorders (Chitaley et al. 2001) and the prolonged enhanced arterial vasoconstriction in heart failure (Hisaoka et al. 2001). There is no information pertaining to the role of the Rho pathway in foeto-placental vasculature during normal pregnancy or in pregnancies complicated by pre eclampsia. The foeto-placental unit is apparently not innervated (Fox & Khong 1990) and hence the regulation of blood flow to the placenta must depend on structural changes, the influence of vaso-active factors and local signalling mechanisms.
It is known that isoprostanes, metabolites of arachidonic acid, are closely linked to the severe vasoconstriction associated with pre eclampsia (Walsh et al. 2000) and can exert their action in part via the Rho kinase pathway (Janssen et al. 2001). Isoprostanes are implicated in the pathogenesis of a wide variety of human disorders and are used extensively as markers of oxidative stress (Roberts & Morrow 2000), with markedly increased levels reported in disorders associated with increased vascular constriction such as in angina (Cipollone et al. 2000), heart failure (Mallat et al. 1998), pulmonary hypertension (Christman 1998) and pre eclampsia (Barden et al. 1996, Staff et al. 1999, Walsh et al. 2000). To date, there are minimal data outlining the potential role of RhoA/Rho kinase in foeto-placental vasculature. First in normal pregnancies and pregnancies complicated by pre eclampsia, and secondly in the vasoconstrictor actions of isoprostanes. Therefore, the aim of this study was twofold. First, to investigate the mRNA expression levels of Rho A, ROCK I and ROCK II in human umbilical artery in normal pregnancies and pregnancies complicated by pre eclampsia. Secondly, to investigate the effects of two isoprostanes, 8-iso PGF2
and 8-iso PGE2, on human umbilical artery tone and to determine if their effects were mediated via the rho kinase pathway.
| Materials and Methods |
|---|
|
|
|---|
RNA extraction and RT
Total RNA was isolated using TRIzol reagent (Life Technologies) (Chomczynski 1993). All RNA samples were DNA-free treated (Ambion Inc., Austin, TX, USA) and checked by standard RT-PCR to ensure that RNA used for real-time fluorescence RT-PCR contained no contaminating genomic DNA. One microgram of RNA (DNA-free treated) (Ambion Inc.) was reverse transcribed into cDNA for use as a template for PCR. The RNA samples were then denatured at 65 °C for 10 min. RTwas performed at 42 °C for 60 min in a reaction volume of 20 µl containing the following: oligo dT primer (500 ng), Moloney murine leukaemia virus (M-MLV) RT buffer (50 mmol l1 TrisHCl pH 8.3, 75 mmol l1 KCl, 3 mmol l1 MgCl2, 10 mmol l 1 dithiothreitol (DTT) (Promega), diethylpyrocarbonate (DEPC)-treated water (BDH, Dorset, England), dNTPs (0.2 mmol l1) (Pro-mega) and 200 U M-MLV reverse transcriptase (Pro-mega). Reverse transcriptase activity was stopped by heating samples at 65 °C for 10 min. Control RNA samples, in which no RT enzyme was added, were included to confirm that no genomic DNA contamination was present.
PCR
Five microlitres of the RT reaction mixture was then used in the subsequent PCR. PCR was performed in a final volume of 50 µl containing 1.5 mmol l1 MgCl2, 20 mmol l1 TrisHCl, 50 mmol l1 KCl pH 8.3 (Life Technologies), 1.25 U Taq DNA polymerase (Life Technologies), 40 µmol l1 dNTPs (Promega) and 0.2 pmol l1 each sense and antisense primer. cDNA amplification was carried out by an initial denaturation step of 5 min at 95 °C followed by 45 cycles of denaturation at 94 °C for 20 s, annealing at 55 °C for 45 s and elongation at 72 °C for 45 s. Five microlitres of each PCR product were then separated by gel electrophoresis on a 1.5% agarose gel. Products were separated alongside a 2-log DNA molecular weight ladder for sizing. Primers used were designed to published DNA and mRNA sequences from GenBank as previously reported (Moran et al. 2002, Friel et al. 2005) (Table 1
).
|
![]() |
500 ng of the DNA-free treated RNA samples, in which no genomic contamination was present, were used in the subsequent one step real-time fluorescence RT-PCR. This reaction was performed in a final volume of 20 µl containing 6 mmol MgCl2 l 1, 0.4 µl enzyme mix, 4 µl reaction mix, 2 µl resolution solution, (Roche Diagnostics GmbH), and 0.3 µmol l1 of each sense and antisense primer. The final volume of 20 µl was achieved using sterile water (Roche Diagnostics GmbH). RT was carried out at 55 °C for 30 min. cDNA amplification was carried out by an initial denaturation step at 95 °C for 30 s, followed by 45 cycles of denaturation at 95 °C with a 5 s hold time, annealing at 55 °C with a 10 s hold time and elongation at 72 °C with a 15 s hold time. The temperature transition rate for the elongation step was 2 °C/s. The temperature transition rate for each step was 20 °C/s unless otherwise stated. Fluorescence data was acquired at the end of each PCR cycle, as previously described (Friel et al. 2005). The LightCycler Software version 3 (fit-points method, Roche), calculated cDNA copy numbers for each gene, generated from their respective amplification curve crossing points (point at which exponential amplification begins) and generated standard curve. This point is equivalent to fluorescence data plotted on the logarithmic scale. Generated cDNA copy numbers for Rho A, ROCK I and ROCK II were then normalised to the housekeeping gene ß-actin. Melting curve analysis was performed by an initial denaturation step of 95 °C, cooling to 65 °C for 10 s and finally gradually increasing the temperature to 95 °C. Fluorescence was measured continually during the melting curve cycle.
10 µl of each PCR product were then separated by gel electrophoresis on a 1.5% (w/v) agarose gel. Products were separated alongside a 2-log DNA molecular weight ladder for sizing. cDNA copy numbers for Rho A, ROCK I and ROCK II generated automatically via the Light-Cycler from their respective standard curves were normalised to the housekeeping gene ß-actin.
Umbilical artery tissue bath experiments
Human umbilical artery was dissected free of Wartons jelly and cut into transverse rings, approximately 35 mm in length. Rings were suspended on stainless-steel hooks and mounted in organ tissue baths under 2 g tension as previously described (Dennedy et al. 2002, Ravikumar et al. 2004). The tissue baths contained 10 ml of KrebsHenseleit physiologic salt solution maintained at 37 °C, pH 7.4 and gassed continuously with 95%O2/ 5%CO2. Individual rings were allowed to equilibrate for at least 90 min, during which time the KrebsHenseleit physiologic salt solution was changed every 15 min. After the equilibration period, rings were challenged with 60 mM KCl. Once the maximum response to KCl was achieved, rings were washed and allowed to equilibrate for 20 min, to allow base-line to be reached again. The KCl challenge was repeated three times. After 40 min of the final KCl washout, either 8-iso PGF2
or 8-iso PGE2 were added in a cumulative manner, at 20 min intervals, at concentrations of 1, 10 and 100 nmol l1 and 1 and 10 µmol l1. The mechanical response of tissues was measured by calculation of the mean amplitude of contraction for 20-min periods using the PowerLab hardware unit and Chart version 3.6 software (AD Instruments, Hastings, UK). The mean amplitude of contraction for the first 20 min (following the 40-min period after the final KCl washout) was calculated and this value served as a control. Antagonism of the effects of 8-iso PGF2
and 8-iso PGE2 were investigated by addition of the rho kinase inhibitor, Y-27632 (10 µmol l1) 30 min prior to the addition of 8- iso PGF2
or 8-iso PGE2. Control strips were simultaneously run with bath exposure to vehicle, but without addition of drug. The effects of 8-iso PGF2
, 8-iso PGE2 alone and with Y-27632 were expressed in terms of g tension generated.
Drugs and solutions
All the chemicals were purchased from Sigma-Aldrich, unless otherwise stated. 8-iso PGF2
and 8-iso PGE2 were obtained from Cayman Chemical, Ann Arbor, MI, USA. A stock solution (10 mmol l1) of 8-iso PGF2
or 8-iso PGE2 was prepared in dimethylsulphoxide (DMSO). Series of dilutions were made with KrebsHenseleit physiologic salt solution on the day of experimentation and maintained at room temperature for the duration of the experiment. Y-27632 was kindly donated by Welfide Corporation, Osaka, Japan. A stock solution (10 mmol l1) of Y-27632 was made with deionised water. Series of dilutions were made with KrebsHenseleit physiologic salt solution on the day of experimentation. A stock solution (100 mmol l1) of indomethacin was made in DMSO. Fresh Krebs-Henseleit physiologic salt solution was made daily.
Statistical analysis
For the mRNA expression study, normalised cDNA copy numbers for each transcript, between both vessel types, were compared using the Students t-test. For the organ tissue bath study, calculated mean g tension for control rings and rings exposed to either 8-iso PGF2
(alone or with Y-27632) and 8-iso PGE2 (alone or with Y-27632) were compared using Students t test. A P value of < 0.05 for the Students t test was considered to be statistically significant. Comparisons of g tension, for each bath concentration of 8-iso PGF2
(alone or with Y-27632) and 8-iso PGE2 (alone or with Y-27632) were performed using ANOVA followed by Sheffe post hoc comparison where appropriate. The statistical package SPSS for Windows version 11 (SPSS Inc., Chicago, Illinois, USA) was used for these statistical calculations. The concentration of drug resulting in half the maximal effect (i.e. the EC50) was measured and represented in pharmacological terms as its appropriate log10 value (i.e. log10 EC50), which is also known as the pD2 value. The mean maximum contractile (MMC) effect is the maximum contractile effect produced by the highest concentration of drug (i.e. 10 µmol l1). Curve fitting was performed with the package Prism (Graphpad Software, San Diego, USA).
| Results |
|---|
|
|
|---|
For organ tissue bath studies umbilical arteries were obtained from a total of 12 women following delivery. Among these 12 women, eight underwent elective caesarean section. The reasons for elective caesarean section included previous caesarean section (n = 2), breech presentation (n = 3), patient request (n = 1), high head (n = 1) and macrosomia (n = 1). The mean patient age (years) ± S.E.M. was 33.50 ± 2.08; median gestation 39.5 weeks (range 3841); parity 0 (n = 6), 1 (n = 4), 2 (n = 1), 3 (n = 1).
Standard RT-PCR
ß-actin, Rho A, ROCK I and ROCK II mRNA expression was detected in all samples (Fig. 1
). Amplification of umbilical artery cDNA with the ß-actin primer set yielded a 377 bp PCR product. Amplification with the Rho A primer set resulted in a 309 bp PCR product and amplification with ROCK I and ROCK II primers yielded 369 and 390 bp products. These products were sequenced (MWG-Biotech Ltd, London UK) and results verified that they were the appropriate parts of the ß-actin, Rho A, ROCK I and ROCK II gene sequences. PCR of the reverse transcriptase negative controls (RT-) showed no amplification confirming the absence of significant genomic DNA contamination. Similarly, the PCR negative control (no cDNA template) showed no amplification. Therefore, RNA in which no genomic contamination was present was used for subsequent quantitative real-time fluorescence RT-PCR.
|
|
|
|
and 8-iso PGE2 exerted a significant concentration-dependent vasocontractile effect on human umbilical artery. This is graphically represented as a histograph in Fig. 4
, and in Fig. 5
were compared by Students t-test. Analysis revealed a significant contractile effect at increasing 8-iso PGF2
concentrations of 1 µmol l1 (P < 0.01) and 10 µmol l1 (P < 0.001). Similarly, calculated increases in g tension for control rings and rings exposed to 8-iso PGE2 were compared by Students t test. Again, analysis revealed a significant contractile effect at increasing 8-iso PGE2 concentrations of 1 (P < 0.001) and 10 µmol l1 (P < 0.001). 8-iso PGE2 induced vasocontractions were significantly greater than those induced by 8-iso PGF2
(P < 0.05). There was no significant difference between pD2 (P > 0.05) values for both compounds.
|
|
|
induced contractions were not significantly antagonised (P > 0.05) (Fig. 4
and 8-iso PGE2 are detailed in Table 3
and 8-iso PGE2 in comparison to 8-iso PGF2
(P > 0.05) and 8-iso PGE2 (P > 0.05) alone. | Discussion |
|---|
|
|
|---|
We have demonstrated that the mRNA expression of Rho A appears to be down regulated in umbilical arteries in association with pre eclampsia. An obvious interpretation of this finding is that there is reduced expression, with presumably reduced activity of the Rho A/Rho kinase pathway in these vessels, in association with pre eclampsia, which may facilitate greater vasodilatation or enhanced foetal blood flow. Therefore, these findings imply that Rho A/ROCK does not influence the increased vasoconstriction seen in association with PET. These data are preliminary, and there are limitations in concluding from these findings. The total RNA for these results was extracted from total human umbilical artery preparations, and hence includes the endothelium and the vascular smooth muscle layer. This was the deliberate design of the experiments, as it would have been technically difficult to denude these vessels, and these samples were all snap frozen in the operating theatre from women with pre eclampsia or normal pregnancy. Further attempts to explore this issue, i.e. to evaluate and quantify Rho A/Rho kinase pathway expression or activity in the vascular smooth muscle, would require methods that are not as accurate in terms of quantitation, such as immunohistochemical techniques. The other issue, which needs to be addressed, is that of the protein expression and that would require Western Blotting experiments. However, as a preliminary finding, it is apparent from our experiments that Rho A is down-regulated at the mRNA level in total umbilical artery vessels from women with pre eclampsia in comparison to control women with normal pregnancies.
It is evident that isoprostanes contribute significantly to the prolonged vasoconstriction that occurs in pre eclampsia. Using umbilical artery ring preparations, with standard in vitro techniques, we have demonstrated that the two isoprostanes 8-iso PGE2 and 8-iso PGF2
, both exert a potent vasoconstrictor effect as has been demonstrated previously (Oliveira et al. 2000). By preincubation with a specific Rho kinase inhibitor, it is clear from our experiments that 8-iso PGE2 is unable to elicit the same response after Rho kinase inhibition, indicative of the fact that the Rho kinase pathway is involved in the vasoconstrictor effect of 8-iso PGE2. These results were not found for the vasoconstrictor of 8-iso PGF2
. There is no obvious reason why the effects of 8-iso PGF2
were apparently different to those of 8-iso PGE2, but it is evident that a different mechanism for 8-iso PGE2 exists, which operates at least in part via the Rho kinase pathway. On speculation, this difference observed in relation to antagonism with Y-27632 can only be due to a relative difference in potencies observed in tissues, whereby 8-iso-PGE2 is more potent (Oliveira et al. 2000, Tazzeo et al. 2003). There are no signalling pathways to our knowledge, known to operate via 8-iso-PGE2 and 8-iso-PGF2
directly. Finally, a further limitation in interpreting these data relate to the fact that, while the cyclooxygenase pathway was blocked, the lipoxygenase pathway was not.
In summary, these findings highlight the potential importance of the Rho A/Rho kinase pathway in the umbilical artery circulation in normal pregnancy, and raise the question of reduced expression at the mRNA level for Rho A in pre eclampsia. The factors regulating these potential changes require further investigation. Future studies include the assessment of the protein expression of the various components of the Rho A/Rho kinase pathway in normal pregnancy and in pregnancies complicated by pre eclampsia. Finally, from a functional point of view, the vasocontractile effect of 8-iso PGE2, a potent isoprostane linked to pre eclampsia appears to be mediated at least in part via the Rho kinase pathway.
| Acknowledgements |
|---|
|
|
|---|
| Footnotes |
|---|
| References |
|---|
|
|
|---|
Barden A, Beilin LJ, Ritchie J, Croft KD, Walters BN & Michael CA 1996 Plasma and urinary 8-iso-prostane as an indicator of lipid peroxidation in pre-eclampsia and normal pregnancy. Clinical Science 91 711718.[Web of Science][Medline]
Byrne B & Morrison JJ 2001 Pre-term birth. In Clinical Evidence, issue 5, pp 9961010. Ed. S Barton. UK British Medical Journal Publishing Group.
Chitaley K, Weber J & Webb RC 2001 Rho A/Rho-kinase, vascular changes and hypertension. Current Hypertension Reports 3 139144.[Medline]
Chomczynski P 1993 A Reagent for single-step simultaneous isolation of RNA. BioTechniques 15 532536.[Web of Science][Medline]
Christman BW 1998 Lipid mediator dysregulation in primary pulmonary hypertension. Chest 114 205S207S.[CrossRef][Web of Science][Medline]
Cipollone F, Ciabattoni G, Patrignami P, Pasquale M, Di Gregorio D, Bucciarelli T, Davi G, Cuccurullo F & Patrono C 2000 Oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina. Circulation 102 10071013.
Curley M, Morrison JJ & Smith TJ 2004 analysis of Maxi-K alpha subunit spice variants in human myometrium. Reproductive Biology and Endocrinology 2 6775.[CrossRef]
Dennedy MC, Houlihan DD, McMillan H & Morrison JJ 2002 Beta2-and beta3-adrenoreceptor agonists: human myometrial selectivity and effects on umbilical artery tone. American Journal of Obstetrics and Gynecology 187 641647.[CrossRef][Web of Science][Medline]
Fleming SM, OGorman T, Finn J, Grimes H, Daly K & Morrison JJ 2000 Cardiac troponin I in pre-eclampsia and gestational hypertension. British Journal of Obstetrics and Gynaecology 107 14171420.[Web of Science]
Fox SB & Khong TY 1990 Lack of innervation of human umbilical cord, An immunohistological and histochemical study. Placenta 11 5962.[Web of Science][Medline]
Friel AM, Curley M, Ravikumar N, Smith TJ & Morrison JJ 2005 Rho A/Rho Kinase mRNA and Protein Levels in Human Myometrium during Pregnancy and Labor. Journal of Society for Gynecologic Investigation 12 2027.
Hisaoka T, Yano M, Ohkusa T, Seutugu M, Ono K, Kohno M, Yamada J, Kobayashi S, Kohno M & Matsuzaki M 2001 Enhancement of Rho/Rho-kinase system in regulation of vascular smooth muscle contraction in tachycardia-induced heart failure. Cardiovascular Research 49 319329.
Janssen LJ, Premji M, Netherton S, Coruzzi J, Lu-Chao H & Cox PG 2001 Vasoconstrictor actions of isoprostanes via tyrosine kinase and Rho kinase in human and canine pulmonary vascular smooth muscles. British Journal of Pharmacology 132 127134.[CrossRef][Web of Science][Medline]
Kunihiko I, Akihiro Y & Koichi S 1999 Major role for the Rho-associated coiled coil forming protein kinase in G-protein-mediated Ca2+ sensitisation through inhibition of myosin phosphatase in rabbit trachea. British Journal of Pharmacology 128 925933.[CrossRef][Web of Science][Medline]
Mallat Z, Philip I, Lebret M, Chatel D, Maclouf J & Tedgui A 1998 Elevated levels of 8-iso-prostaglandin F2alpha in pericardial fluid of patients with heart failure: a potential role for in vivo oxidant stress in ventricular dilation and progression to heart failure. Circulation 97 15361539.
Moran CJ, Friel AM, Smith TJ, Cairns M & Morrison JJ 2002 Expression and modulation of Rho kinase in human pregnant myometrium. Molecular Human Reproduction 8 196200.
Oliveira L, Stallwood NA & Crankshaw DJ 2000 Effects of some isoprostanes on the human umbilical artery in vitro. British Journal of Pharmacology 129 509514.[CrossRef][Web of Science][Medline]
Ravikumar N, Houlihan DD & Morrison JJ 2004 Effects of polyamines on human umbilical artery tone in vitro. Journal of Society for Gynecologic Investigation 11 536539.[CrossRef]
Roberts LJ II & Morrow JD 2000 Measurement of F2-isoprostanes as an index of oxidative stress in vivo. Free Radicals in Biology and Medicine 28 505523.[CrossRef]
Roberts JM & Cooper DW 2001 Pathogenesis and genetics of pre-eclampsia. Lancet 357 5356.[CrossRef][Web of Science][Medline]
Somlyo AP & Somlyo AV 2000 Signal transduction by G-proteins, Rho-kinase and protein phosphatase to smooth muscle and non-muscle myosin II. Journal of Physiology 522 177185.
Staff AC, Halvorsen B, Ranheim T & Henriksen T 1999 Elevated level of free 8-iso-prostaglandin F2
in the decidua basalis of women with preeclampsia. American Journal Obstetrics and Gynecology 181 12111215.[CrossRef]
Tazzeo T, Miller J & Janssen LT 2003 Vasoconstrictor responses, and underlying mechanisms, to isoprostanes in human and porcine bronchial arterial smooth muscle. British Journal of Pharmacology 140 759763.[CrossRef][Web of Science][Medline]
Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T & Morishita T 1997 Calcium sensitisation of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 389 990994.[CrossRef][Medline]
Walker JJ 2000 Pre-eclampsia. Lancet 356 12601265.[CrossRef][Web of Science][Medline]
Walsh SW, Vaughan JE & Roberts LJ II 2000 Placental isoprostane is significantly increased in preeclampsia. Federation of American Societies for Experimental Biology Journal 14 12891296.
This article has been cited by other articles:
![]() |
C. Nicola, A. Chirpac, P. K. Lala, and C. Chakraborty Roles of Rho Guanosine 5'-Triphosphatase A, Rho Kinases, and Extracellular Signal Regulated Kinase (1/2) in Prostaglandin E2-Mediated Migration of First-Trimester Human Extravillous Trophoblast Endocrinology, March 1, 2008; 149(3): 1243 - 1251. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |